Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?; [Katheterablation bei Vorhofflimmern – gibt es einen Mortalitätsvorteil bei Patienten mit Diabetes und Herzinsuffizienz?]

Atrial fibrillation (AF) is the most commonly sustained arrhythmia, and patients with diabetes mellitus (DM) exhibit an increased incidence of AF. Besides DM, heart failure (HF) shares pathophysiological links with AF, mainly related to the pathological remodeling of hearts affected by structural disease. As in a vicious circle, AF may contribute to HF worsening and increased mortality in patients with structural heart diseases, and the outcome may be further impaired when concomitant DM is present. Although no data directly referring to DM patients with HF are available, indirect information can be drawn from large studies on patients with HF and AF. The present review discusses the outcome of AF ablation in patients with DM and HF, focusing on safety, efficacy, and most particularly on hard endpoints such as mortality and thromboembolic event incidence. © 2019, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.